Nevertheless, given the small number of patients with ALK/EGFR positive NSCLC, it is likely that the worldwide incidence of oligoprogressive disease is significantly greater in the setting of metastatic breast cancer. This evidence concerns the gene EGFR and non-small cell lung carcinoma.